Phase 3 TRIUMPH-2 data presented at EASD show HbA1c reductions up to 1.6%, with GI effects, hypotension, and dysesthesia as key counseling points.
|Videos|November 2, 2015
How Updated Beers Criteria Will Affect Pharmacists' Practice
Todd Semla, MS, PharmD, BCPS, FCCP, AGSF, of the Department of Veterans Affairs explains how the AGS 2015 Beers Criteria will affect pharmacists' practice.
Advertisement
Todd Semla, MS, PharmD, BCPS, FCCP, AGSF, of the Department of Veterans Affairs explains how the AGS 2015 Beers Criteria will affect pharmacists' practice.
This video was recorded at ASCP's Annual Meeting and Exposition in October 2015 in Las Vegas, Nevada.
Advertisement
Related to this article
In a FINE-HEART analysis, cancer history raised the risk of death and hospitalization but did not blunt finerenone's cardiovascular and kidney benefits.
Hemoglobin, platelets, bleeding, pericardial effusions, and intrapulmonary shunting top the monitoring list for patients with pulmonary arterial hypertension (PAH) starting with sotatercept, according to Vallerie McLaughlin, MD.
Marie-Claire Seeley, PhD, MNurs, RN, discusses standing tests, medication review, and what inflammatory findings may mean for future POTS treatment.
AI-driven coding fuels specialty EHRs and telehealth tools, making ePrescribing faster, tailored, and affordable while shifting focus to workflow and compliance.
Approval spans early and levodopa-treated disease; a 6-week titration and CYP3A interactions put pharmacists at the center of starting therapy.
Novo Nordisk's top-line phase 3 data show 12.4% weight loss with CagriSema 1.0 mg/1.0 mg in type 2 diabetes and 21.0% in adults with overweight or obesity.
Researchers found substantial overlap in autonomic symptoms, orthostatic tachycardia, and functional impairment between long COVID and POTS.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Tiratricol, First Treatment for MCT8 Deficiency
2
Pharmacists Can Close CKD Medication Adherence Gaps, PHTI Says
3
FDA Approves Tavapadon, First D1/D5 Agonist for Parkinson Disease
4
Expert Q&A: Researcher Urges Autonomic Assessment for Patients With Long COVID
5